Garry Pairaudeau is currently Head of Hit Discovery at AstraZeneca; the group comprising HTS, Comp Chem, Virtual screening and DEL is responsible for generating high quality starting points for AstraZeneca. In addition, the group works extensively with academic centres of excellence through open innovation and strategic collaborations with groups such as MRC, CRUK, Life Arc and many others to help support academic drug discovery.
Garry also chairs the Global Chemistry Leadership team in AstraZeneca responsible for chemistry strategy and has been particularly active in building Automation and Machine learning capabilities.
He has experience leading projects through all phases of Drug Discovery contributing to multiple clinical candidates in the respirator,y inflammation and CV areas. He has a long standing interest in lead generation, innovation, in chemistry, hit identification and diversity screening. Prior to taking up his current position in 2012 he was Director of Chemistry for the cardiovascular research area at Alderley Park.
November 13, 2019
- 12:50 pmPanel: Connectivity, Automation and Information – driving innovation in drug discovery